Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Tejas Savant maintains an Underweight rating on Veracyte (NASDAQ:VCYT) but raises the price target from $21 to $26.
August 12, 2024 | 5:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley analyst Tejas Savant maintains an Underweight rating on Veracyte but raises the price target from $21 to $26.
The Underweight rating suggests a bearish outlook, but the raised price target indicates some positive expectations. The mixed signals may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100